Read by QxMD icon Read

Hematology/oncology and Stem Cell Therapy

Mahmoud Aljurf, Faisal Rawas, Randa Alnounou, Nasir Bakshi, Naeem Chaudhri, Salem Khalil, Fahad Almohareb, Maher Albitar
No abstract text is available yet for this article.
November 9, 2016: Hematology/oncology and Stem Cell Therapy
Maher Alainawi, Rouba Shaker, Aya Eltraboulsi, Samir Akel, Nadine Yazbeck, Hassan El Solh, Samar Muwakkit
No abstract text is available yet for this article.
November 9, 2016: Hematology/oncology and Stem Cell Therapy
Pierre Tannous, Zubin Mukadam, Chetan Kammari, Harsha Banavasi, Ayman O Soubani
OBJECTIVE/BACKGROUND: The use of computed tomography pulmonary angiography (CTPA) in the emergency department (ED) for patients suspected to have pulmonary embolism (PE) has been steadily rising in the last 2decades. However, there are limited studies that specifically address the use of CTPA in the ED for cancer patients suspected to have PE. The objective of this study is to assess the rate of positive PE by CTPA in the ED in cancer patients and the variables that are associated with positive results...
December 2016: Hematology/oncology and Stem Cell Therapy
Vandana Kamath, Kiruthiga Kala Gnanasekaran, Joy Mammen
OBJECTIVE/BACKGROUND: May-Hegglin anomaly (MHA) is a rare familial bleeding disorder characterized by a triad of thrombocytopenia, giant platelets, and Döhle-like inclusion bodies within the leukocytes. The clinical spectrum as well as the pathophysiology of this entity is not well defined. The objective of this work is to present a series of three cases of MHA diagnosed in our hospital, where the patients presented with variable bleeding manifestations, thrombocytopenia, and giant platelets...
December 2016: Hematology/oncology and Stem Cell Therapy
Shouki Bazarbashi, Ayman Omar, Ali Aljubran, Ahmad Alzahrani, Nasser Alsanea, Alaa Abduljabbar, Samar Alhomoud, Luai Ashari, Khalid Balaraj, Hussein Soudy, Mohammad Neimatallah, Musa Fagih
BACKGROUND: Achieving a high rate of complete pathological response with pre-operative chemoradiotherapy in rectal cancer is an unmet need. We evaluated the efficacy and toxicity of the combination of cetuximab, capecitabine and radiation therapy in the pre-operative setting of localized rectal cancer. PATIENTS AND METHODS: Patients with clinically staged T3, T4 or nodepositive rectal cancer were treated with concurrent capecitabine and radiotherapy with weekly cetuximab starting one week before the start of radiation...
December 2016: Hematology/oncology and Stem Cell Therapy
Flávio Augusto Naoum, Breno Pannia Espósito, Rodolfo Delfini Cançado
No abstract text is available yet for this article.
December 2016: Hematology/oncology and Stem Cell Therapy
Mireille Crampe, Jennifer Garry, Stephen E Langabeer, Philip T Murphy
No abstract text is available yet for this article.
December 2016: Hematology/oncology and Stem Cell Therapy
Arezoo Kiaei, Habib Onsori, Aylar Alijani, Sasan Andalib, Saeid Ghorbian, Ebrahim Sakhinia
OBJECTIVE/BACKGROUND: Specific chromosomal translocations are found in human leukemias and lymphomas. These translocations are closely related to particular histological and immunological phenotypes. In Burkitt's lymphoma, translocation t(8;14)(q24;q32), which involves the c-myc gene (8q24) and the immunoglobulin heavy-chain (IgH) locus (14q32), accounts for 90-95% of all chromosomal translocations. This translocation can be found in 2-5% of diffuse large B-cell lymphoma (DLBCL). Long-distance polymerase chain reaction (LD-PCR) assays, which can identify oncogene/Ig gene rearrangement, can detect these fusion genes...
December 2016: Hematology/oncology and Stem Cell Therapy
Panagiotis J Vlachostergios, Katerina G Oikonomou, Adnan Hussain, Rakesh Abbi, Rajeev L Balmiki
No abstract text is available yet for this article.
December 2016: Hematology/oncology and Stem Cell Therapy
Neelesh Reddy, Baswantrao Malipatil, Satish Kumar
We describe the association of familial multiple subcutaneous lipomatosis with a PALB2 gene mutation (c.2716delT) and its increased predilection to cancers.
December 2016: Hematology/oncology and Stem Cell Therapy
Jessica El-Asmar, Rebecca Gonzalez, Ryan Bookout, Asmita Mishra, Mohamed A Kharfan-Dabaja
Allogeneic hematopoietic cell transplantation is a potential curative treatment option for various malignant and nonmalignant hematologic disorders. Patients undergoing an allogeneic hematopoietic cell transplant are prescribed immune-suppressant therapies to facilitate hematopoietic donor-cell engraftment and prevent graft-versus-host disease. Drug-drug interactions may occur, owing to exposure to complex multidrug regimens with narrow therapeutic windows and high toxicity profiles. Here, we describe a unique case of a 65-year-old man with poor-risk acute myeloid leukemia who underwent a matched-sibling hematopoietic cell allograft...
December 2016: Hematology/oncology and Stem Cell Therapy
Igor Stoma, Igor Karpov, Anatoly Uss, Oleg Rummo, Natalia Milanovich, Igor Iskrov
OBJECTIVE/BACKGROUND: A decision about the need for antimicrobial therapy in a patient with febrile neutropenia after hematopoietic stem cell transplantation (HSCT) is often complicated because of the low frequency of culture isolation and reduced clinical manifestation of infection. Usefulness and choice of sepsis biomarkers to distinguish bloodstream infection (BSI) from other causes of febrile episode is still argued in HSCT recipients in modern epidemiological situations characterized by the emergence of highly resistant gram-negative microorganisms...
October 20, 2016: Hematology/oncology and Stem Cell Therapy
Alireza Khabazi, Mahafarin Maralani, Sasan Andalib, Ebrahim Sakhinia
Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is a periodic fever syndrome inherited in an autosomal dominant fashion. It stems from mutations in the TNFRSF1A gene that expresses the receptor for tumor necrosis factor α. A patient with TRAPS may present with prolonged episodes of fever attacks, abdominal pain, severe myalgia, and painful erythema on the trunk or extremities. Here, we report the case of an 8-year-old boy with febrile attacks occurring every 1-2months and continuing for 3-4days...
October 19, 2016: Hematology/oncology and Stem Cell Therapy
Ryo Hanajiri, Takeshi Kobayashi, Kosuke Yoshioka, Daisuke Watanabe, Kyoko Watakabe, Yutaka Murata, Takeshi Hagino, Yasushi Seno, Yuho Najima, Aiko Igarashi, Noriko Doki, Kazuhiko Kakihana, Hisashi Sakamaki, Kazuteru Ohashi
OBJECTIVE/BACKGROUND: Here, we described the clinical characteristics and outcomes of central nervous system (CNS) infections occurring after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a single institution over the previous 6 years. METHODS: Charts of 353 consecutive allogeneic transplant recipients were retrospectively reviewed for CNS infection. RESULTS: A total of 17 cases of CNS infection were identified at a median of 38 days (range, 10-1028 days) after allo-HSCT...
September 17, 2016: Hematology/oncology and Stem Cell Therapy
Hossein Ayatollahi, Arezoo Shajiei, Mohammad Hadi Sadeghian, Maryam Sheikhi, Ehsan Yazdandoust, Masumeh Ghazanfarpour, Seyyede Fatemeh Shams, Sepideh Shakeri
OBJECTIVE/BACKGROUND: Acute myeloid leukemia (AML) is defined as leukemic blast reproduction in bone marrow. Chromosomal abnormalities form different subgroups with joint clinical specifications and results. t(8;21)(q22;q22) and inv(16)(p13;q22) form core binding factor-AML (CBF-AML). c-kit mutation activation occurs in 12.8-46.1% of adults with CBF leukemia. These mutations occur in 20-25% of t(8;21) and 30% of inv(16) cases. METHODS: In this systematic review, we searched different databases, including PubMed, Scopus, and Embase...
September 3, 2016: Hematology/oncology and Stem Cell Therapy
Iman Abou Dalle, Samer Nassif, Ali Bazarbachi
Pathologic increase in bone marrow reticulin fibrosis can be present in many malignant hematopoietic diseases. In acute leukemia, one-third of patients have some degree of marrow reticulin fibrosis at presentation, which is thought to be related to cytokine release from blasts. Marrow fibrosis is particularly common in acute megakaryoblastic leukemia, while this change is rarely seen in acute promyelocytic leukemia. Six case reports of acute promyelocytic leukemia with marrow reticulin fibrosis have been described so far in the literature...
September 2, 2016: Hematology/oncology and Stem Cell Therapy
Shweta Kambali, Asma Taj
Polycythemia vera is one of the chronic myeloproliferative diseases and very few patients present with its actual clinical manifestations. The most common findings are increased red cell mass and an increased leukocyte count with decreased erythropoietin. We present a case where there was a delay in the diagnosis of polycythemia because of menorrhagia in the past. On admission, the patient presented with elevated red and white blood cell counts, erythropoietin was low, and polycythemia was then suspected. A bcr-abl test was performed to rule out chronic myelogenous leukemia...
September 2, 2016: Hematology/oncology and Stem Cell Therapy
Stephen E Langabeer, Karl Haslam
No abstract text is available yet for this article.
September 2, 2016: Hematology/oncology and Stem Cell Therapy
Marco Pizzi, Usama Gergis, Felicia Chaviano, Attilio Orazi
BACKGROUND/OBJECTIVE: Hematopoietic stem cell transplant (HSCT) is the only curative treatment for myeloproliferative neoplasm-associated myelofibrosis (MPN-MF). The main clinical manifestation of MPN-MF is splenomegaly secondary to extramedullary hematopoiesis (EMH). The effects of HSCT on splenic EMH and associated vascular and stromal changes are unknown. This study compares the findings seen in spleens following HSCT with those of nontransplanted patients, normal controls, and matched bone marrow (BM) samples...
September 2016: Hematology/oncology and Stem Cell Therapy
Karl Haslam, Eibhlin Conneally, Catherine M Flynn, Mary R Cahill, Oonagh Gilligan, Derville O'Shea, Stephen E Langabeer
Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of essential thrombocythemia (ET) and primary myelofibrosis (PMF). Given the diagnostic and emerging prognostic significance of these mutations, in addition to the geographical heterogeneity reported, the incidence of CALR mutations was determined in an Irish cohort of patients with MPNs with a view to incorporate this analysis into a prospective screening program...
September 2016: Hematology/oncology and Stem Cell Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"